AI Drug Developer Pathos Raises $237 Million Series E at $3 Billion Valuation
Start here
Pathos, an AI-driven drug development company, has raised $237 million in a Series E round led by Bristol Myers Squibb, valuing the company at roughly $3 billion. The company plans to use the funding to expand beyond oncology into neurological diseases such as Alzheimer's, drawing on Tempus AI data and its partnership with BMS. Its proprietary model, Foundry, deploys thousands of agents that calculate the probability of success for clinical assets, informing drug selection, population choice and trial design. How quickly the expansion into neurology progresses and what the new capital delivers in terms of clinical programs remain open questions.
Written by a model from the reports · updated 3 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- statnews.comPickSTAT+: AI drug firm Pathos raises $237 million, pushing valuation to $3 billion
AI drug developer Pathos announced a $237 million Series E round led by Bristol Myers Squibb, valuing the company at about $3 billion. The company will use Tempus AI data and work with BMS to expand from oncology into neurological diseases such as Alzheimer's. Its proprietary model, Foundry, runs thousands of agents that calculate the probability of success for clinical assets, guiding drug selection, population choice, and trial design.
Heat trend for this story
Heat now 14·Peak in the comparable set 15 (Oct 23 21:00)·Change over 24h in the comparable set +53%·Participants now 2
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.